Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-04-11 7:55 pm Purchase | 2024-04-01 | 13G | CervoMed Inc. CRVO | RA CAPITAL MANAGEMENT L.P. | 825,373 9.990% | 825,373 (New Position) | Filing History |
| 2024-04-11 4:16 pm Purchase | 2024-04-11 | 13D | Acrivon Therapeutics, Inc. Common Stock ACRV | RA CAPITAL MANAGEMENT L.P. | 8,359,102 27.100% | 3,541,743 (+73.52%) | Filing History |
| 2024-04-04 7:04 pm Purchase | 2024-03-25 | 13G | Dyne Therapeutics, Inc. DYN | RA CAPITAL MANAGEMENT L.P. | 5,213,661 6.400% | 5,213,661 (New Position) | Filing History |
| 2024-04-01 7:33 pm Purchase | 2024-03-20 | 13G | Sera Prognostics, Inc. SERA | RA CAPITAL MANAGEMENT L.P. | 2,047,221 6.500% | 2,047,221 (New Position) | Filing History |
| 2024-03-29 5:41 pm Purchase | 2024-03-27 | 13D | Nkarta, Inc. NKTX | RA CAPITAL MANAGEMENT L.P. | 13,848,371 18.900% | 6,016,031 (+76.81%) | Filing History |
| 2024-03-29 4:14 pm Purchase | 2024-03-27 | 13D | ARS Pharmaceuticals, Inc. SPRY | RA CAPITAL MANAGEMENT L.P. | 10,860,977 11.300% | 1,401,299 (+14.81%) | Filing History |
| 2024-03-29 12:54 pm Purchase | 2024-03-19 | 13G | Alto Neuroscience, Inc. ANRO | RA CAPITAL MANAGEMENT L.P. | 1,385,491 5.200% | 1,385,491 (New Position) | Filing History |
| 2024-03-28 4:16 pm Purchase | 2024-03-21 | 13D | LENZ Therapeutics, Inc. LENZ | RA CAPITAL MANAGEMENT L.P. | 4,250,856 16.600% | 4,250,856 (New Position) | Filing History |
| 2024-03-25 4:18 pm Purchase | 2024-03-14 | 13G | Regulus Therapeutics Inc. RGLS | RA CAPITAL MANAGEMENT L.P. | 6,250,000 9.500% | 6,250,000 (New Position) | Filing History |
| 2024-03-25 4:17 pm Purchase | 2024-03-14 | 13G | Cybin Inc. CYBN | RA CAPITAL MANAGEMENT L.P. | 1,529,988 7.700% | 1,529,988 (New Position) | Filing History |
| 2024-03-18 4:46 pm Purchase | 2024-03-14 | 13D | Climb Bio, Inc. CLYM | RA CAPITAL MANAGEMENT L.P. | 13,179,181 47.500% | 2,778 (+0.02%) | Filing History |
| 2024-03-11 7:56 pm Unchanged | 2024-03-07 | 13D | PepGen Inc. PEPG | RA CAPITAL MANAGEMENT L.P. | 10,695,135 33.100% | 0 (Unchanged) | Filing History |
| 2024-03-06 6:54 pm Purchase | 2024-03-04 | 13D | Janux Therapeutics, Inc. JANX | RA CAPITAL MANAGEMENT L.P. | 10,593,395 19.990% | 1,922,751 (+22.18%) | Filing History |
| 2024-03-06 6:50 pm Purchase | 2024-03-04 | 13D | 89bio, Inc. ETNB | RA CAPITAL MANAGEMENT L.P. | 14,254,298 14.800% | 1,378,443 (+10.71%) | Filing History |
| 2024-02-27 4:19 pm Sale | 2024-02-23 | 13D | Connect Biopharma Holdings Limited CNTB | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -3,062,871 (Position Closed) | Filing History |
| 2024-02-26 4:17 pm Purchase | 2024-02-16 | 13G | Larimar Therapeutics, Inc. LRMR | RA CAPITAL MANAGEMENT L.P. | 6,045,351 9.500% | 6,045,351 (New Position) | Filing History |
| 2024-02-22 7:07 pm Unchanged | 2023-12-31 | 13G | Cytek Biosciences, Inc. CTKB | RA CAPITAL MANAGEMENT L.P. | 6,809,404 5.200% | 0 (Unchanged) | Filing History |
| 2024-02-21 4:17 pm Sale | 2024-02-19 | 13D | Icosavax, Inc. ICVX | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -5,985,843 (Position Closed) | Filing History |
| 2024-02-14 9:08 pm Sale | 2023-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | RA CAPITAL MANAGEMENT L.P. | 3,095,136 6.100% | -313,570 (-9.20%) | Filing History |
| 2024-02-14 6:41 pm Purchase | 2023-12-31 | 13G | Unicycive Therapeutics, Inc. UNCY | RA CAPITAL MANAGEMENT L.P. | 347,211 9.990% | 142 (+0.04%) | Filing History |